Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509316 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL2636631 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL15263324 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL2010790 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL4436402 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL5182595 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL1994115 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL9393256 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| Water SCHEMBL5144372 | 0.99 | HIF1A (0.42) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL7643809 | 0.90 | PYGL (0.38) | HIF1AADORA2AADORA2BLMNANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108603176-A | Virus-free cell lines and methods of obtaining same | 格里科贝克有限责任公司 | 2018-09-28 | — | — | CN | claimed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | claimed |
| US-20100247482-A1 | TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2010-09-30 | — | — | US | claimed |
| WO-2010059204-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND RELATED DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2010-05-27 | — | — | WO | claimed |
| US-20090220435-A1 | TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009099676-A1 | TYPE 5 ADENYLYL CYCLASE INHIBITORS FOR PROVIDING CARDIAC PROTECTION | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2009-08-13 | — | — | WO | claimed |
| EP-1919939-A2 | TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY | Nastech Pharmaceutical Company Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | claimed |
| WO-2007014391-A2 | TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-02-01 | — | — | WO | claimed |
| US-6271212-B1 | MIXTURE WITH CARRIER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2001-08-07 | — | — | US | claimed |
| EP-0841936-A1 | CONJUGATION-STABILIZED THERAPEUTIC AGENT COMPOSITIONS, DELIVERY AND DIAGNOSTIC FORMULATIONS | PROTEIN DELIVERY, INC. (US) | 1998-05-20 | — | — | EP | claimed |
| US-5681811-A | THERAPEUTIC AGENT COUPLED WITH SYNTHETIC POLYMER COMPRISING LIPOPHILIC AND HYDROPHILIC MOIETIES BALANCED SO COMPOSITION IS SOLUBLE AND ABLE TO INTERACT WITH BIOLOGICAL MEMBRANES | PROTEIN DELIVERY, INC. (US) | 1997-10-28 | — | — | US | claimed |
| EP-0642525-B1 | Nucleosides being O-acylated with a mono-unsaturated omega-9 C18 or C20 fatty acid | NORSK HYDRO AS (NO) | 1997-05-02 | — | — | EP | claimed |
| WO-1997004796-A1 | CONJUGATION-STABILIZED THERAPEUTIC AGENT COMPOSITIONS, DELIVERY AND DIAGNOSTIC FORMULATIONS | PROTEIN DELIVERY, INC. (US) | 1997-02-13 | — | — | WO | claimed |
| EP-0716856-A2 | Therapeutic uses of 2',5'-oligoadenylate derivatives | Temple University of the Commonwealth System of Higher Education (US) | 1996-06-19 | — | — | EP | claimed |
| EP-0420872-A4 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | — | 1992-10-21 | — | — | EP | claimed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | claimed |
| WO-1989012380-A2 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HI (US) | 1989-12-28 | — | — | WO | claimed |
| EP-0106309-A2 | Biologically active extracts, process for their manufacture, medicinal and cosmetical preparations comprising them, and their use as additives in foodstuffs and stimulants | Gauri, Kailash Kumar, Dr. Prof. (DE) | 1984-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | HIF1A 1870/4885ADORA2A 389/4885ADORA2B 687/4885 |
| US-20090220435-A1 | TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS | VIP, FABP2, EPCAM | HIF1A 2512/4885ADORA2A 3640/4885ADORA2B 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.